纤克颗粒对博莱霉素致肺纤维化大鼠TNF-α细胞因子表达影响的研究
|
摘要
目的:观察纤克颗粒对肺纤维化大鼠不同时期TNF-α表达的影响,以证实纤克颗粒对肺纤维化的防治作用。
方法:本研究采用博莱霉素诱导肺纤维化大鼠模型。将筛选清洁级Wistar大鼠108只,用随机数字表法分为6组,正常对照组,模型组,强的松组,纤克颗粒低剂量组,纤克颗粒中剂量组和纤克颗粒高剂量组,每组18只。普通专用饲料喂养。造模后第二天开始正常对照组、模型组按10ml/kg体重的标准灌服生理盐水,强的松组按5g/kg体重、纤克颗粒高、中、低剂量组分别按10g/kg、5g/kg、2.5g/kg体重灌服纤克颗粒水溶液。分别于连续给药的第7天、14天和28天后,腹主动脉取血,采用ELISA测定各时期血清中TNF-α含量。
结果:大鼠TNF-α的表达,各时期模型组的表达均较高,较其它组有显著的差异(p<0.01),其中第7天达到高峰,随后逐渐下降,但仍高于其它组;强的松组与中药高、中、低剂量组的表达高于正常组,低于模型组。第7天TNF-α的表达从高到低的次序为中药低剂量组、强的松组、中药高剂量组、中药中剂量组;第14天TNF-α的表达的高低次序为中药低、高剂量组、强的松组、中药中剂量组;第28天TNF-α的表达的高低次序为中药低剂量组、强的松组、中药高、中剂量组。三个时期,强的松组与中药中剂量组相比有明显差异(p<0.05),与中药高、低剂量组相比无差异(p>0.05);中药高、低剂量组均与中剂量组存在显著差异(p<0.05或p<0.01)。
结论:纤克颗粒可有效抑制大鼠体重的下降,较模型组相比均存在明显差异(p<0.05或p<0.01)。纤克颗粒中剂量可明显降低各时期肺纤维化大鼠TNF-α含量,与强的松组相比有较明显的差异(p<0.05),说明纤克颗粒对肺纤维化有较明显的防治作用,其作用机制可能与其抑制TNF-α的表达有关。
Purpose: To observe XianKe Granule on pulmonary fibrosis in rats at different times of the effects of TNF-αand in order to confirm preventment and treatment of XianKe Granule on pulmonary fibrosis.
Methods: In this study, bleomycin-induced pulmonary fibrosis in rats. Wistar rats of clean grade the filter 108, using random number table is divided into six groups, normal control group, model group, prednisone group, XianKe Granule low-dose group, middle-dose group and high-dose group, 18 rats in each group. Ordinary special feed were fed. Beginning the day after modeling the normal control group, model group, the standard weight according to 10ml/kg fed with normal saline, prednisolone group by 5g/kg weight, XianKe Granule of high, middle and low-dose groups respectively 10g/kg, 5g/kg, 2.5g/kg weight of XianKe Granule aqueous solution. Continuous administration, respectively, the 7th, 14th and 28th day, the abdominal aorta blood, using ELISA in serum were determined during the TNF-αlevels.
Results: Rats’TNF-αexpression of various periods in model group were higher than other groups differ significantly(p<0.01), which reached the peak on the 7th day, then decreased gradually, but still were higher than others’; the expressions of prednisone group and XianKe Granule high, middle and low-dose group were higher than the normal group, lower than the model group.On the 7th day the expressions of TNF-αin order from high to low were XianKe Granule low-dose group, prednisone group, high-dose group and middle-dose group. On the 14th day the order from high to low were XianKe Granule low-dose group, high-dose group, prednisone group and middle-dose group.The order of the 28th day is the same as the 7th’s order. In various periods, prednisone group compared with the XianKe Granule middle-dose group were significantly different (p<0.05), and the other XianKe Granule group were not significant difference (p>0.05); high-and low-dose group and the middle dose group were significantly different (p<0.05 or p<0.01).
Conclusion: XianKe Granule could inhibit weight declining, compared with the model group were significantly difference (p<0.05 or p<0.01). XianKe Granule middle-dose can significantly reduce the different periods of pulmonary fibrosis in rat TNF-αcontent, compared with the prednisone group were the obvious difference (p<0.05), and that shows XianKe Granule to pulmonary fibrosis have more obviously preventive and therapeutic effects, its mechanism may be related to inhibiting the expression of TNF-α.
方法:本研究采用博莱霉素诱导肺纤维化大鼠模型。将筛选清洁级Wistar大鼠108只,用随机数字表法分为6组,正常对照组,模型组,强的松组,纤克颗粒低剂量组,纤克颗粒中剂量组和纤克颗粒高剂量组,每组18只。普通专用饲料喂养。造模后第二天开始正常对照组、模型组按10ml/kg体重的标准灌服生理盐水,强的松组按5g/kg体重、纤克颗粒高、中、低剂量组分别按10g/kg、5g/kg、2.5g/kg体重灌服纤克颗粒水溶液。分别于连续给药的第7天、14天和28天后,腹主动脉取血,采用ELISA测定各时期血清中TNF-α含量。
结果:大鼠TNF-α的表达,各时期模型组的表达均较高,较其它组有显著的差异(p<0.01),其中第7天达到高峰,随后逐渐下降,但仍高于其它组;强的松组与中药高、中、低剂量组的表达高于正常组,低于模型组。第7天TNF-α的表达从高到低的次序为中药低剂量组、强的松组、中药高剂量组、中药中剂量组;第14天TNF-α的表达的高低次序为中药低、高剂量组、强的松组、中药中剂量组;第28天TNF-α的表达的高低次序为中药低剂量组、强的松组、中药高、中剂量组。三个时期,强的松组与中药中剂量组相比有明显差异(p<0.05),与中药高、低剂量组相比无差异(p>0.05);中药高、低剂量组均与中剂量组存在显著差异(p<0.05或p<0.01)。
结论:纤克颗粒可有效抑制大鼠体重的下降,较模型组相比均存在明显差异(p<0.05或p<0.01)。纤克颗粒中剂量可明显降低各时期肺纤维化大鼠TNF-α含量,与强的松组相比有较明显的差异(p<0.05),说明纤克颗粒对肺纤维化有较明显的防治作用,其作用机制可能与其抑制TNF-α的表达有关。
Purpose: To observe XianKe Granule on pulmonary fibrosis in rats at different times of the effects of TNF-αand in order to confirm preventment and treatment of XianKe Granule on pulmonary fibrosis.
Methods: In this study, bleomycin-induced pulmonary fibrosis in rats. Wistar rats of clean grade the filter 108, using random number table is divided into six groups, normal control group, model group, prednisone group, XianKe Granule low-dose group, middle-dose group and high-dose group, 18 rats in each group. Ordinary special feed were fed. Beginning the day after modeling the normal control group, model group, the standard weight according to 10ml/kg fed with normal saline, prednisolone group by 5g/kg weight, XianKe Granule of high, middle and low-dose groups respectively 10g/kg, 5g/kg, 2.5g/kg weight of XianKe Granule aqueous solution. Continuous administration, respectively, the 7th, 14th and 28th day, the abdominal aorta blood, using ELISA in serum were determined during the TNF-αlevels.
Results: Rats’TNF-αexpression of various periods in model group were higher than other groups differ significantly(p<0.01), which reached the peak on the 7th day, then decreased gradually, but still were higher than others’; the expressions of prednisone group and XianKe Granule high, middle and low-dose group were higher than the normal group, lower than the model group.On the 7th day the expressions of TNF-αin order from high to low were XianKe Granule low-dose group, prednisone group, high-dose group and middle-dose group. On the 14th day the order from high to low were XianKe Granule low-dose group, high-dose group, prednisone group and middle-dose group.The order of the 28th day is the same as the 7th’s order. In various periods, prednisone group compared with the XianKe Granule middle-dose group were significantly different (p<0.05), and the other XianKe Granule group were not significant difference (p>0.05); high-and low-dose group and the middle dose group were significantly different (p<0.05 or p<0.01).
Conclusion: XianKe Granule could inhibit weight declining, compared with the model group were significantly difference (p<0.05 or p<0.01). XianKe Granule middle-dose can significantly reduce the different periods of pulmonary fibrosis in rat TNF-αcontent, compared with the prednisone group were the obvious difference (p<0.05), and that shows XianKe Granule to pulmonary fibrosis have more obviously preventive and therapeutic effects, its mechanism may be related to inhibiting the expression of TNF-α.
引文
[1]叶任高,陆再英.内科学(第六版).人民卫生出版社,2004;2:95-96.
[2] Amy L.Olson,Jeffrey J.Swigris,Dennis C.Lezotte,et al.Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med.,2007;176:277-284.
[3]赵兰才,武维屏.肺间质纤维化的中医研究进展述评(综述).北京中医药大学学报,2000;23(4):70-72.
[4]梁群.肺间质纤维化的中医药治疗进展.中医药信息,2004;21(3):13-15.
[5]智屹惠.曹世宏教授论治肺间质纤维化.南京中医药大学学报(自然科学版),2001;17(3):185-186.
[6]陈燕,吴继全.晁恩祥治疗肺间质纤维化临证思辨特点.世界中医药,2007;2(2):90-92.
[7]盛刚,郭珍,任月朗.从肺痹论治特发性肺间质纤维化.山东中医药大学学报,2008;32(1):25-26.
[8]焦扬,周平安.肺间质纤维化的病因病机和辨证论治述要.北京中医,2007;26(10):651-652.
[9]王海彤,武维平.中医药治疗弥漫性肺间质纤维化信息讨论.中国中医药信息杂志,1996;3(7):25-26.
[10]王新华,张弘,徐志瑛.特发性肺间质纤维化的中西医结合治疗.贵阳中医学院学报,22(4):3-4.
[11]关天宇,焦扬,孙海燕.中医对肺间质纤维化的认识.中华中医药学,2007;25(5):1000-1003.
[12]仝润芍.血府逐瘀汤加减治疗弥漫性间质性肺炎46例.河南中医,1996;16(4):233.
[13]张纾难,晁恩祥.对急性型特发性肺纤维化治疗难点的思考.中国中医急症,1998;7(4):176-178.
[14]张会川.中药治疗特发性急性肺间质纤维化1例.北京中医药大学学报,1998;21(6):69.
[15]孙增涛.间质性肺疾病的中医治疗.中国乡村医生杂志,1999;12:13-14.
[16]赵勤萍.肺间质纤维化中医证治探讨.山西中医学院学报,2005;6(1):34-35.
[17]荆阳,付小燕.从毒论治肺间质纤维化.四川省卫生管理干部学院学报,2006;25(1):58-60.
[18]徐志瑛.肺络为病——论肺间质纤维化.浙江中西医结合杂志,2009;19(6):331-332.
[19]崔红生,邱冬梅,武维屏.肺间质纤维化从络病辨治探析.中医杂志,2003;44(12):946-947.
[20]姜良铎,张晓梅,肖培新.特发性肺间质纤维化的病因论治.北京中医药,2008;27(4):252-254.
[21]赵勤萍.肺间质纤维化中医证治探讨.山西中医学院学报,2005;6(1):34-35.
[22]彭清,辛建保,苏良平,等.黄芪对肺纤维化大鼠MMP22和TMP21表达的影响.华中科技大学学报(医学版),2006;36(1):35-56.
[23]骆维东.中药丹参对肺纤维化作用的研究进展.中华实用中西医杂志,2004;4(17):1457-1458.
[24]蒋玉宇,曹世宏,孙子凯.当归干预肺间质纤维化的作用途径研究.辽宁中医杂志,2006;33(11):1501-1502.
[25]王少杰,白文,王春玲,等.人工冬虫夏草菌液对博莱霉素致小鼠肺纤维化的保护作用.中国中药杂志,2007;32(24):2623-2627.
[26]齐曼古丽·吾守尔,夏宇,哈木拉提·吾甫尔,等.喘消雾化液对博莱霉素诱导大鼠肺纤维化模型SOD和MDA水平的影响.新疆医科大学学报,2005;28(6):503-507.
[27]陈小囡,田菊霞,陈河,等.红豆杉活性成分巴卡亭Ⅲ对大鼠肺纤维化的干预作用.浙江中医杂志,2009;44(3):192-193.
[28]陆雄,叶伟成,刘平,等.扶正化瘀方对博莱霉素诱发大鼠肺间质纤维化的干预作用.中医杂志,2006;47(7):538-540.
[29]张欣,辛洪涛,李怀臣,等.芪丹颗粒对鼠肺间质纤维化转化生长因子β1mRNA和肿瘤坏死因子αmRNA表达的影响.中国临床康复,2005;9(31):144-146.
[30]辛洪涛,宋秀杰,徐少华,等.芪丹颗粒剂对大鼠肺间质纤维化时TGF-B和TNF-α表达的影响.首都医科大学学报,2004;25(1):49-53.
[31]刘恩顺,孙增涛,廉富,等.芪术合剂干预肺纤维化大鼠TGF-β1mRNA表达的实验研究.天津药学,2007;19(2):1-3.
[32]杨惠琴,李风森.试论益气活血法治疗肺间质纤维化.新疆医科大学学报,2008;31(6):737.
[33]徐波,张淑文,贺正一,等.中药复方861治疗大鼠肺纤维化的实验研究.中医药学报,2005;33(1):44-46.
[34]陈靖,柴瑞华.活络化痰法对肺间质纤维化影响的实验研究.山西中医,2007;23(6):57-58.
[35]庞立健,王琳琳,吕晓东.参龙煎剂对博莱霉素致大鼠肺纤维化模型HYP表达的影响.山东中医杂志,2007;26(12):851-853.
[36]张天嵩,韩镭,吴银根,等.肺纤煎对博莱霉素A5致肺纤维化鼠肺组织TNF-αTNF-αmRNA表达的影响.中医药学刊,2004;22(8):1474-1476.
[37]甘卉,刘大程,王岚,等.润肺治纤汤对实验性肺纤维化模型大鼠治疗作用的研究.中国老年学杂志,2007;3:521-523.
[38]付大海,雷瑗琳,张彦.通络补益汤配合西药治疗特发性肺间质纤维化30例.甘肃中医,2008;21(8):39-40.
[39]徐杰,刘兴奎.血府逐瘀汤防治平阳霉素引起肺纤维化的实验研究.中医药信息,2000;1:49-50.
[40]宋建平,李伟,李瑞琴,等.《金匮要略》不同方药对肺纤维化大鼠模型早期阶段(1-14d)的影响——肺纤维化早期阶段中医基本病机探讨.中国中医基础医学杂志,2009;15(6):432-434.
[41]宋建平,刘方州,李伟,等.金匮肾气丸对肺纤维化大鼠肺组织中肿瘤坏死因子α表达的影响.中成药,2006;28(1):78-81.
[42]周志光,周珊,汪顺清.百合固金丸治疗特发性肺纤维化20例总结.湖南中医杂志,2006;22(5):15-16.
[43]李戎,闫智勇,李文军,等.艾灸“肺俞”“膏肓”对BLMA5诱导大鼠肺纤维化的影响.中国针灸,2004;24(3):204-207.
[44]李戎,李文军,蔡永宁,等.艾灸“肺俞”“膏肓”对BLMA5诱导肺纤维化大鼠肺组织肿瘤坏死因子α的影响.辽宁中医杂志,2005;32(4):354-355.
[45]李戎,李文军,蔡永宁,等.艾灸“肺俞”“膏肓”影响BLMA5诱导肺纤维化大鼠TGF-β1表达实验研究.中国针灸,2005;25(11):790-792.
[46]中华医学会呼吸病学分会.特发性肺(间质)纤维化诊断与治疗指南(草案).中华结核和呼吸杂志,2002;25(7):387-389.
[47]周彩存,袁淮平,许启霞,等.糖皮质激素对肺间质纤维化的治疗作用.蚌埠医学院学报,2000;25(2):84-85.
[48]刘金苹,翟乃亮,范贤明,等.地塞米松对肺纤维化大鼠肺组织STAT1和PDGF表达的影响.医学研究杂志,2009;2:40-42.
[49]李惠萍,李霞,何国钧,等.地塞米松对博莱霉素致肺间质纤维化大鼠肺内炎性细胞的影响.复旦学报(医学版),2004;31(4):378-382.
[50]迟翔宇,李怀臣,牟晓燕,等.环孢菌素A对大鼠肺纤维化的治疗作用.山东医科大学学报,2001;39(2):121-123.
[51] PhD Roderick Phillips, MD Tony Wang Lawrence M. Pirfenidone mediates differential effects on lipopolysaccharide-induced cytokine expression in human peripheral mononuclear cells. CHEST,2005;128(4):169s.
[52] Raghu G,Johnson WC,Lockhart D,et al. Am J Respire Crit Care Med,l999;159(41):1061-1069.
[53] Mansoor JK, Chen AT,Schelegle ES,et al.Effect of dies-ingested pirfenidone on pulmonary function,cardiovasculature and blood gas measurements in rats.Res Commun Mol Pathol Pharmacol,1999;103(3):260-286.
[54] Hagiwara,Ishii,Kitamura.Nacetylcysteine Represses Bleomycin-induced Lung Injury. Am J Respir Crit Care Med,2000;162:225–231.
[55]袁胜,徐启勇,叶燕青,等.氨溴索对实验性肺纤维化的干预作用.武汉大学学报(医学版),2005;3:165-167.
[56] Lasky JA, Ortiz LA. Antifibrotic therapy for the treatment of pulmonary fibrosis. Am J Med Sci,2001;322:213-221.
[57]留永健.氯沙坦对博莱霉素导致的大鼠肺纤维化模型的干预作用及其可能机制.中国协和医科大学博士研究生论文,2001;10.
[58]王媛.氯沙坦(losartan)对博莱霉素致大鼠肺纤维化的干预机制.河北医科大学硕士研究生毕业论文,2008;3.
[59]高晓方,崔社怀.干扰素γ对实验大鼠肺纤维化的治疗作用及机制的初步研究.第三军医大学学报,2005;27(2):143-145.
[60] Piguet PF,Vesin C. Treatment by human recombinant soluble TNF-a receptorof pulmonary fibrosis induced by bleomycin or silica in mice. Eur. ResPir J,1994;7:515.
[61]胡顺鹏,何英,李志军.血必净联合前列腺素E1应用对肺纤维化大鼠肿瘤坏死因子-α的影响.辽宁中医杂志,2008;35(11):1767-1768.
[62]谭伟,刘新民,何冰,等.红霉素对肺间质纤维化的治作用及机理探讨.中华结核和呼吸杂志,1999;22(1):46-47.
[63]马靖,何冰,李楠,等.阿奇霉素对博莱霉素致大鼠肺损伤干预作用及其机制的探讨.中华结核和呼吸杂志,2002;7:392-395.
[64]孙燕妮,顾宗元,王雄彪,等.内皮素受体拮抗剂对博莱霉素所致大鼠肺纤维化模型的影响.临床和实验医学杂志,2007;6(6):7-9.
[65]蔡志刚.醛固酮拮抗剂对大鼠肺纤维化的干预作用及其作用机制.河北医科大学硕士研究生毕业论文,2004;3.
[66] Hiroshi Kubo, Katsutoshi Nakayama, Masaru Yanai, et al. Anticoagulant Therapy for Idiopathic Pulmonary Fibrosis. Chest,2005;128:1475-1482.
[67]黄玉芳,马承立,刘书盈.特发性肺纤维化的发病机制及抗凝治疗研究进展.山东医药,2006;46(34):77-78.
[68]张宏印,李电东.博莱霉素作用机制研究进展.国外医药抗生素分册,1999;20(6):266-269.
[69]李军,陈汝贤.博莱霉素族抗生素研究概况.中国新药杂志,2003;12(8):612-615.
[70]王世鑫.二氧化硅粉尘致肺纤维化机制及早期生物标记物研究.重庆大学博士论文,2004;10.
[71]李曙芳,刘田福,郭民,等.五味子乙素对二氧化硅致大鼠肺损伤的保护作用.中国比较医学杂志,2009;19(5):30-34.
[72] Jeffrey L. Spees, Derek A. Pociask, Deborah E. Sullivan, et al. Engraftment of Bone Marrow Progenitor Cells in a Rat Model of Asbestos-Induced Pulmonary Fibrosis. Am. J. Respir. Crit. CareMed.,2007;176:385-394.
[73]胡晓玲.免疫复合物致大鼠肺间质纤维化作用的研究.青岛大学医学院学报,2004;40(2):112-116.
[74]王和枚,瞿文生,余寿忠,等.胺碘酮所致大鼠肺毒性.中国药理学与毒理学杂志,1999;13(4):301一305.
[75] Jeffrey W. Card, William J. Racz, James F. Brien, et al. Differential Effects of Pirfenidone on Acute Pulmonary Injury and Ensuing Fibrosis in the Hamster Model of Amiodarone-Induced Pulmonary Toxicity. Toxicological Sciences,2003;75:169–180.
[76]孔璐,王继峰,牛建照,等.气管内一次性注入博来霉素诱发大鼠肺损伤的动态变化.中国现代医学杂志,2004;14(24):14-21.
[77]张伟,鲁香凤,张晓梅,等.气管插管快速灌注博来霉素复制大鼠肺间质纤维化模型.中西医结合学报,2008;6(1):60-67.
[78]姜晓妹,王孝铭,刘晓滨.雾化吸入平阳霉素法致小白鼠肺纤维化的观察.哈尔滨医科大学学报,1995;29(1):4-5.
[79]刘珊,范桂香,袁育康,等.两种小鼠肺纤维化造模方法的比较.西安交通大学学报(医学版),2004;25(3):244-249.
[80]张纾难,韩春生.一种新的肺纤维化造模方法.中日友好医院学报,1997;11(4):283-285.
[81]张晓晔,志村早苗,增田辙,等.博莱霉素静脉注射制备小鼠肺间质纤维化动物模型.中国实验动物学报,2007;15(4):242-244.
[82]张晓晔,宁欣,刘卫青,等.静脉注射和气管内滴注博来霉素诱导小鼠肺纤维化的差异.中国实验动物学报,2008:16(3):176-178.
[83] Adamson IY,Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.Am J Patrol,1974;77(2):185-197.
[84]齐曼古丽·吾守尔,夏宇,巴哈尔古丽·米吉提,等.博莱霉素致大鼠肺纤维化模型的建立方法及比较.新疆医科大学学报,2005;28(6):495-498.
[85]王梅,傅强,闵碧荷,等.磷酸羟基哌喹对大鼠放射性肺纤维化的防治作用.中国癌症杂志,2002;12(6):519一521.
[86]臧倩,杨明会.放射性肺损伤大鼠血清白细胞介素-6和肿瘤坏死因子-α的动态变化中国中西医结合急救杂志,2007;14(2):88-90.
[87] Muggia FM,Louie AC,Sikic BI.Pulmonary toxicity of antitumor agents.Cancer Treat Rev,1983;10:221-243.
[88] Felix C,Jack G,Geoffrey J.Pulmonary fibrosis searching for model answers.Am J Respire Cell Mol Biol,2005;33:9-13.
[89] Forgone MA,Cap A,Liao R,et al. Heterozygous cellular glutathione peroxide deficiency in the mouse:abnormalities in vascular and cardiac function and structure. Circulation,2002;106(9):1154.
[90]孔琪,秦川.肺纤维化的发病机制及关键靶点.国外医学呼吸系统分册,2005;25(5):331-336.
[91] Coker PK,Laurent GJ. Anticytokine approaches in pulmonary fibrosis:bringing factors into focus.Thorax,1997;52:294-296.
[92]袁志明,陈光瑾,杜文彬.大鼠肺纤维化过程中肺泡巨噬细胞释放白细胞介素6和肿瘤坏死因子α的观察.天津医药,1999;27(12):742-743.
[93]孔琪,秦川.肺纤维化的发病机制及关键靶点.国外医学呼吸系统分册,2005;25(5):331-336.
[94]牟晓燕,林殿杰,辛洪涛.肺间质纤维化的分子生物学发病机制及治疗新进展.国际呼吸杂志,2006;26(12):928-931.
[95] Flieger D, Spengler U, Beier I,et al. Enhancement of antibody dependent cellular cytotoxicity(ADCC) by combination of cytokines. Hybridoma,1999;18:63-68.
[96] Sullivan DE,Ferris M,Pociask D,et al. Tumor necrosis factor-αinduces transforming growth factor-βexpression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell MolBiol,2005;32:342.
[97] Panagiotis Pantelidis, Gregory C. Fanning, Athol U. Wells, et al. Analysis of Tumor Necrosis Factor-a, Lymphotoxin-a, Tumor Necrosis Factor Receptor II, and Interleukin-6 Polymorphisms in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med, 2001;163:1432–1436.
[98] Piguet PF, Kaufman S, Barazzone C,et al. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis.Int J Exp Pathol,1997;78:43–48.
[2] Amy L.Olson,Jeffrey J.Swigris,Dennis C.Lezotte,et al.Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med.,2007;176:277-284.
[3]赵兰才,武维屏.肺间质纤维化的中医研究进展述评(综述).北京中医药大学学报,2000;23(4):70-72.
[4]梁群.肺间质纤维化的中医药治疗进展.中医药信息,2004;21(3):13-15.
[5]智屹惠.曹世宏教授论治肺间质纤维化.南京中医药大学学报(自然科学版),2001;17(3):185-186.
[6]陈燕,吴继全.晁恩祥治疗肺间质纤维化临证思辨特点.世界中医药,2007;2(2):90-92.
[7]盛刚,郭珍,任月朗.从肺痹论治特发性肺间质纤维化.山东中医药大学学报,2008;32(1):25-26.
[8]焦扬,周平安.肺间质纤维化的病因病机和辨证论治述要.北京中医,2007;26(10):651-652.
[9]王海彤,武维平.中医药治疗弥漫性肺间质纤维化信息讨论.中国中医药信息杂志,1996;3(7):25-26.
[10]王新华,张弘,徐志瑛.特发性肺间质纤维化的中西医结合治疗.贵阳中医学院学报,22(4):3-4.
[11]关天宇,焦扬,孙海燕.中医对肺间质纤维化的认识.中华中医药学,2007;25(5):1000-1003.
[12]仝润芍.血府逐瘀汤加减治疗弥漫性间质性肺炎46例.河南中医,1996;16(4):233.
[13]张纾难,晁恩祥.对急性型特发性肺纤维化治疗难点的思考.中国中医急症,1998;7(4):176-178.
[14]张会川.中药治疗特发性急性肺间质纤维化1例.北京中医药大学学报,1998;21(6):69.
[15]孙增涛.间质性肺疾病的中医治疗.中国乡村医生杂志,1999;12:13-14.
[16]赵勤萍.肺间质纤维化中医证治探讨.山西中医学院学报,2005;6(1):34-35.
[17]荆阳,付小燕.从毒论治肺间质纤维化.四川省卫生管理干部学院学报,2006;25(1):58-60.
[18]徐志瑛.肺络为病——论肺间质纤维化.浙江中西医结合杂志,2009;19(6):331-332.
[19]崔红生,邱冬梅,武维屏.肺间质纤维化从络病辨治探析.中医杂志,2003;44(12):946-947.
[20]姜良铎,张晓梅,肖培新.特发性肺间质纤维化的病因论治.北京中医药,2008;27(4):252-254.
[21]赵勤萍.肺间质纤维化中医证治探讨.山西中医学院学报,2005;6(1):34-35.
[22]彭清,辛建保,苏良平,等.黄芪对肺纤维化大鼠MMP22和TMP21表达的影响.华中科技大学学报(医学版),2006;36(1):35-56.
[23]骆维东.中药丹参对肺纤维化作用的研究进展.中华实用中西医杂志,2004;4(17):1457-1458.
[24]蒋玉宇,曹世宏,孙子凯.当归干预肺间质纤维化的作用途径研究.辽宁中医杂志,2006;33(11):1501-1502.
[25]王少杰,白文,王春玲,等.人工冬虫夏草菌液对博莱霉素致小鼠肺纤维化的保护作用.中国中药杂志,2007;32(24):2623-2627.
[26]齐曼古丽·吾守尔,夏宇,哈木拉提·吾甫尔,等.喘消雾化液对博莱霉素诱导大鼠肺纤维化模型SOD和MDA水平的影响.新疆医科大学学报,2005;28(6):503-507.
[27]陈小囡,田菊霞,陈河,等.红豆杉活性成分巴卡亭Ⅲ对大鼠肺纤维化的干预作用.浙江中医杂志,2009;44(3):192-193.
[28]陆雄,叶伟成,刘平,等.扶正化瘀方对博莱霉素诱发大鼠肺间质纤维化的干预作用.中医杂志,2006;47(7):538-540.
[29]张欣,辛洪涛,李怀臣,等.芪丹颗粒对鼠肺间质纤维化转化生长因子β1mRNA和肿瘤坏死因子αmRNA表达的影响.中国临床康复,2005;9(31):144-146.
[30]辛洪涛,宋秀杰,徐少华,等.芪丹颗粒剂对大鼠肺间质纤维化时TGF-B和TNF-α表达的影响.首都医科大学学报,2004;25(1):49-53.
[31]刘恩顺,孙增涛,廉富,等.芪术合剂干预肺纤维化大鼠TGF-β1mRNA表达的实验研究.天津药学,2007;19(2):1-3.
[32]杨惠琴,李风森.试论益气活血法治疗肺间质纤维化.新疆医科大学学报,2008;31(6):737.
[33]徐波,张淑文,贺正一,等.中药复方861治疗大鼠肺纤维化的实验研究.中医药学报,2005;33(1):44-46.
[34]陈靖,柴瑞华.活络化痰法对肺间质纤维化影响的实验研究.山西中医,2007;23(6):57-58.
[35]庞立健,王琳琳,吕晓东.参龙煎剂对博莱霉素致大鼠肺纤维化模型HYP表达的影响.山东中医杂志,2007;26(12):851-853.
[36]张天嵩,韩镭,吴银根,等.肺纤煎对博莱霉素A5致肺纤维化鼠肺组织TNF-αTNF-αmRNA表达的影响.中医药学刊,2004;22(8):1474-1476.
[37]甘卉,刘大程,王岚,等.润肺治纤汤对实验性肺纤维化模型大鼠治疗作用的研究.中国老年学杂志,2007;3:521-523.
[38]付大海,雷瑗琳,张彦.通络补益汤配合西药治疗特发性肺间质纤维化30例.甘肃中医,2008;21(8):39-40.
[39]徐杰,刘兴奎.血府逐瘀汤防治平阳霉素引起肺纤维化的实验研究.中医药信息,2000;1:49-50.
[40]宋建平,李伟,李瑞琴,等.《金匮要略》不同方药对肺纤维化大鼠模型早期阶段(1-14d)的影响——肺纤维化早期阶段中医基本病机探讨.中国中医基础医学杂志,2009;15(6):432-434.
[41]宋建平,刘方州,李伟,等.金匮肾气丸对肺纤维化大鼠肺组织中肿瘤坏死因子α表达的影响.中成药,2006;28(1):78-81.
[42]周志光,周珊,汪顺清.百合固金丸治疗特发性肺纤维化20例总结.湖南中医杂志,2006;22(5):15-16.
[43]李戎,闫智勇,李文军,等.艾灸“肺俞”“膏肓”对BLMA5诱导大鼠肺纤维化的影响.中国针灸,2004;24(3):204-207.
[44]李戎,李文军,蔡永宁,等.艾灸“肺俞”“膏肓”对BLMA5诱导肺纤维化大鼠肺组织肿瘤坏死因子α的影响.辽宁中医杂志,2005;32(4):354-355.
[45]李戎,李文军,蔡永宁,等.艾灸“肺俞”“膏肓”影响BLMA5诱导肺纤维化大鼠TGF-β1表达实验研究.中国针灸,2005;25(11):790-792.
[46]中华医学会呼吸病学分会.特发性肺(间质)纤维化诊断与治疗指南(草案).中华结核和呼吸杂志,2002;25(7):387-389.
[47]周彩存,袁淮平,许启霞,等.糖皮质激素对肺间质纤维化的治疗作用.蚌埠医学院学报,2000;25(2):84-85.
[48]刘金苹,翟乃亮,范贤明,等.地塞米松对肺纤维化大鼠肺组织STAT1和PDGF表达的影响.医学研究杂志,2009;2:40-42.
[49]李惠萍,李霞,何国钧,等.地塞米松对博莱霉素致肺间质纤维化大鼠肺内炎性细胞的影响.复旦学报(医学版),2004;31(4):378-382.
[50]迟翔宇,李怀臣,牟晓燕,等.环孢菌素A对大鼠肺纤维化的治疗作用.山东医科大学学报,2001;39(2):121-123.
[51] PhD Roderick Phillips, MD Tony Wang Lawrence M. Pirfenidone mediates differential effects on lipopolysaccharide-induced cytokine expression in human peripheral mononuclear cells. CHEST,2005;128(4):169s.
[52] Raghu G,Johnson WC,Lockhart D,et al. Am J Respire Crit Care Med,l999;159(41):1061-1069.
[53] Mansoor JK, Chen AT,Schelegle ES,et al.Effect of dies-ingested pirfenidone on pulmonary function,cardiovasculature and blood gas measurements in rats.Res Commun Mol Pathol Pharmacol,1999;103(3):260-286.
[54] Hagiwara,Ishii,Kitamura.Nacetylcysteine Represses Bleomycin-induced Lung Injury. Am J Respir Crit Care Med,2000;162:225–231.
[55]袁胜,徐启勇,叶燕青,等.氨溴索对实验性肺纤维化的干预作用.武汉大学学报(医学版),2005;3:165-167.
[56] Lasky JA, Ortiz LA. Antifibrotic therapy for the treatment of pulmonary fibrosis. Am J Med Sci,2001;322:213-221.
[57]留永健.氯沙坦对博莱霉素导致的大鼠肺纤维化模型的干预作用及其可能机制.中国协和医科大学博士研究生论文,2001;10.
[58]王媛.氯沙坦(losartan)对博莱霉素致大鼠肺纤维化的干预机制.河北医科大学硕士研究生毕业论文,2008;3.
[59]高晓方,崔社怀.干扰素γ对实验大鼠肺纤维化的治疗作用及机制的初步研究.第三军医大学学报,2005;27(2):143-145.
[60] Piguet PF,Vesin C. Treatment by human recombinant soluble TNF-a receptorof pulmonary fibrosis induced by bleomycin or silica in mice. Eur. ResPir J,1994;7:515.
[61]胡顺鹏,何英,李志军.血必净联合前列腺素E1应用对肺纤维化大鼠肿瘤坏死因子-α的影响.辽宁中医杂志,2008;35(11):1767-1768.
[62]谭伟,刘新民,何冰,等.红霉素对肺间质纤维化的治作用及机理探讨.中华结核和呼吸杂志,1999;22(1):46-47.
[63]马靖,何冰,李楠,等.阿奇霉素对博莱霉素致大鼠肺损伤干预作用及其机制的探讨.中华结核和呼吸杂志,2002;7:392-395.
[64]孙燕妮,顾宗元,王雄彪,等.内皮素受体拮抗剂对博莱霉素所致大鼠肺纤维化模型的影响.临床和实验医学杂志,2007;6(6):7-9.
[65]蔡志刚.醛固酮拮抗剂对大鼠肺纤维化的干预作用及其作用机制.河北医科大学硕士研究生毕业论文,2004;3.
[66] Hiroshi Kubo, Katsutoshi Nakayama, Masaru Yanai, et al. Anticoagulant Therapy for Idiopathic Pulmonary Fibrosis. Chest,2005;128:1475-1482.
[67]黄玉芳,马承立,刘书盈.特发性肺纤维化的发病机制及抗凝治疗研究进展.山东医药,2006;46(34):77-78.
[68]张宏印,李电东.博莱霉素作用机制研究进展.国外医药抗生素分册,1999;20(6):266-269.
[69]李军,陈汝贤.博莱霉素族抗生素研究概况.中国新药杂志,2003;12(8):612-615.
[70]王世鑫.二氧化硅粉尘致肺纤维化机制及早期生物标记物研究.重庆大学博士论文,2004;10.
[71]李曙芳,刘田福,郭民,等.五味子乙素对二氧化硅致大鼠肺损伤的保护作用.中国比较医学杂志,2009;19(5):30-34.
[72] Jeffrey L. Spees, Derek A. Pociask, Deborah E. Sullivan, et al. Engraftment of Bone Marrow Progenitor Cells in a Rat Model of Asbestos-Induced Pulmonary Fibrosis. Am. J. Respir. Crit. CareMed.,2007;176:385-394.
[73]胡晓玲.免疫复合物致大鼠肺间质纤维化作用的研究.青岛大学医学院学报,2004;40(2):112-116.
[74]王和枚,瞿文生,余寿忠,等.胺碘酮所致大鼠肺毒性.中国药理学与毒理学杂志,1999;13(4):301一305.
[75] Jeffrey W. Card, William J. Racz, James F. Brien, et al. Differential Effects of Pirfenidone on Acute Pulmonary Injury and Ensuing Fibrosis in the Hamster Model of Amiodarone-Induced Pulmonary Toxicity. Toxicological Sciences,2003;75:169–180.
[76]孔璐,王继峰,牛建照,等.气管内一次性注入博来霉素诱发大鼠肺损伤的动态变化.中国现代医学杂志,2004;14(24):14-21.
[77]张伟,鲁香凤,张晓梅,等.气管插管快速灌注博来霉素复制大鼠肺间质纤维化模型.中西医结合学报,2008;6(1):60-67.
[78]姜晓妹,王孝铭,刘晓滨.雾化吸入平阳霉素法致小白鼠肺纤维化的观察.哈尔滨医科大学学报,1995;29(1):4-5.
[79]刘珊,范桂香,袁育康,等.两种小鼠肺纤维化造模方法的比较.西安交通大学学报(医学版),2004;25(3):244-249.
[80]张纾难,韩春生.一种新的肺纤维化造模方法.中日友好医院学报,1997;11(4):283-285.
[81]张晓晔,志村早苗,增田辙,等.博莱霉素静脉注射制备小鼠肺间质纤维化动物模型.中国实验动物学报,2007;15(4):242-244.
[82]张晓晔,宁欣,刘卫青,等.静脉注射和气管内滴注博来霉素诱导小鼠肺纤维化的差异.中国实验动物学报,2008:16(3):176-178.
[83] Adamson IY,Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.Am J Patrol,1974;77(2):185-197.
[84]齐曼古丽·吾守尔,夏宇,巴哈尔古丽·米吉提,等.博莱霉素致大鼠肺纤维化模型的建立方法及比较.新疆医科大学学报,2005;28(6):495-498.
[85]王梅,傅强,闵碧荷,等.磷酸羟基哌喹对大鼠放射性肺纤维化的防治作用.中国癌症杂志,2002;12(6):519一521.
[86]臧倩,杨明会.放射性肺损伤大鼠血清白细胞介素-6和肿瘤坏死因子-α的动态变化中国中西医结合急救杂志,2007;14(2):88-90.
[87] Muggia FM,Louie AC,Sikic BI.Pulmonary toxicity of antitumor agents.Cancer Treat Rev,1983;10:221-243.
[88] Felix C,Jack G,Geoffrey J.Pulmonary fibrosis searching for model answers.Am J Respire Cell Mol Biol,2005;33:9-13.
[89] Forgone MA,Cap A,Liao R,et al. Heterozygous cellular glutathione peroxide deficiency in the mouse:abnormalities in vascular and cardiac function and structure. Circulation,2002;106(9):1154.
[90]孔琪,秦川.肺纤维化的发病机制及关键靶点.国外医学呼吸系统分册,2005;25(5):331-336.
[91] Coker PK,Laurent GJ. Anticytokine approaches in pulmonary fibrosis:bringing factors into focus.Thorax,1997;52:294-296.
[92]袁志明,陈光瑾,杜文彬.大鼠肺纤维化过程中肺泡巨噬细胞释放白细胞介素6和肿瘤坏死因子α的观察.天津医药,1999;27(12):742-743.
[93]孔琪,秦川.肺纤维化的发病机制及关键靶点.国外医学呼吸系统分册,2005;25(5):331-336.
[94]牟晓燕,林殿杰,辛洪涛.肺间质纤维化的分子生物学发病机制及治疗新进展.国际呼吸杂志,2006;26(12):928-931.
[95] Flieger D, Spengler U, Beier I,et al. Enhancement of antibody dependent cellular cytotoxicity(ADCC) by combination of cytokines. Hybridoma,1999;18:63-68.
[96] Sullivan DE,Ferris M,Pociask D,et al. Tumor necrosis factor-αinduces transforming growth factor-βexpression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell MolBiol,2005;32:342.
[97] Panagiotis Pantelidis, Gregory C. Fanning, Athol U. Wells, et al. Analysis of Tumor Necrosis Factor-a, Lymphotoxin-a, Tumor Necrosis Factor Receptor II, and Interleukin-6 Polymorphisms in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med, 2001;163:1432–1436.
[98] Piguet PF, Kaufman S, Barazzone C,et al. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis.Int J Exp Pathol,1997;78:43–48.